Tissue Dissociation Enzymes for Islets & Other Cells

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$572,658.00
Award Year:
2004
Program:
SBIR
Phase:
Phase I
Contract:
1R43DK065467-01A1
Award Id:
71530
Agency Tracking Number:
DK065467
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
1102 Stadium Drive, INDIANAPOLIS, IN, 46202
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
ROBERT MCCARTHY
(317) 917-3457
vitacyte@indy.rr.com
Business Contact:
ROBERT MCCARTHY
(317) 917-3457
RMCCARTHY@INDY.RR.COM
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Tissue dissociation enzyme (TDE) products have not been improved for over 50 years. "Crude collagenase" products contain collagenases and other proteases used to free cells from collagen rich, extracellular matrix. They are derived from minimally purified culture supernatants of Clostridium histolyticum. Collagenases are the key enzymes; they alone initiate the degradation of collagen. Once initiated, other proteases in the product help it rapidly degrade collagen. TDE products can be improved significantly if the key enzymes responsible for collagen degradation from C. histolyticum are identified, purified, and optimized to maximize the yield and quality of specific cells recovered from tissue. This approach led to the development of Liberase HITM, which was shown to be significantly superior to crude collagenase in recovering islets from human pancreata. This improvement contributed to the success of the "Edmonton protocol", a breakthrough in using islet transplantation to treat adult, Type I, brittle diabetic patients. Further improvements are required in the development, manufacture, and application of purified, islet specific; TDE's to increase islet recovery from human pancreata. Currently, most centers use 2-4 organs to recover a sufficient number of islets for transplantation. This ratio must be reduced to 1:1 organ donor to recipient ratio to move this procedure from research to routine clinical practice. The 3 aims of my Grant address this problem. 1) I will prepare a purified, islet specific TDE mixture that meets specifications used in clinical islet transplantation protocols. Higher quality collagenase will be used in this preparation based on improvements in the raw material, purification, and characterization of the purified enzymes. This TDE preparation will be compared to similar products for its stability, enzyme activity, and ability to recover islets from human pancreata. 2) I will develop a robust assay to assess collagenase in mixtures containing other proteolytic enzymes. This assay will assess the quality and stability of current TDE products used to isolate islets. It will also be used to monitor changes in collagenase during the course of human pancreas digestion. 3) I will identify those enzymes, which efficiently degrade native collagen. This fills a gap in the scientific literature since highly purified collagenase and other proteases will be used in these experiments. This knowledge offers the potential to use fewer, more effective enzymes in TDE mixtures, leading to increases in the yield and quality of cells recovered from any mammalian organ.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government